01/02/2026
📣 A Historic Moment for Proton Therapy!
A Phase III randomized trial providing Level 1 evidence, published in The Lancet, shows a significant survival benefit for patients with oropharyngeal cancer treated with proton therapy compared to traditional radiation.
Key findings include:
• 10% higher five-year overall survival
• 42% reduction in the hazard of death
• Significantly reduced severe toxicities, including less feeding tube dependence, dry mouth, swallowing difficulty, and immune suppression
Led by researchers at The University of Texas MD Anderson Cancer Center, this multi-institutional study is the largest of its kind and the first to demonstrate a survival advantage for proton therapy.
The National Association for Proton Therapy is now calling for immediate access for appropriate patients.
Ackerman Cancer Center is proud to offer proton therapy and to align with evidence-based advancements that improve both outcomes and quality of life.
👉 The Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01962-2/abstract
